Resources

News

October 30, 2023

AlivaMab Biologics Announces Two Bispecific Antibody Presentations at SITC 2023

Well-validated platforms for biologics discovery and engineering including T-cell engagers SAN DIEGO, Calif. – October 30, 2023 – AlivaMab Biologics, LLC (“AMB”), ...
CONTINUE READING

October 16, 2023

AlivaMab Discovery Services Changes Name to AlivaMab Biologics, Reflecting Its Continuing Expansion and Evolution

Launching new and expanded capabilities providing end-to-end solutions in biologics discovery and engineering SAN DIEGO, Calif. – October 16, 2023 ...
CONTINUE READING

April 10, 2023

AlivaMab Discovery Services Appoints Ankita Srivastava, PhD, as Vice President, Antibody Engineering and Protein Sciences

Veteran with breadth and depth of multispecific antibody drug discovery to evolve ADS’ capabilities SAN DIEGO, Calif. – April 10, ...
CONTINUE READING

November 15, 2022

Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities

New platforms and capabilities further enable partners to advance better antibody drugs faster. SAN DIEGO, Calif. – November 15, 2022 ...
CONTINUE READING

September 23, 2022

AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer

SAN DIEGO, Calif. – September 23, 2022 – AlivaMab Discovery Services (“ADS”), a leader in the discovery of superior antibody-based ...
CONTINUE READING

January 31, 2022

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development

Ablexis’ multi-target licensing agreement grants Almirall rights to use the AlivaMab® Mouse technology for research, development and commercialization of antibodies ...
CONTINUE READING

January 11, 2022

AlivaMab Discovery Services Appoints Jane Seagal, PhD, as Vice President of Antibody Discovery

AbbVie veteran to support rapid growth and new technologies. SAN DIEGO, Calif. – January 11, 2022 – AlivaMab Discovery Services (“ADS”), a ...
CONTINUE READING

November 1, 2021

AlivaMab Discovery Services Expands Discovery Agreement with IGM Biosciences

Expanded agreement aims to accelerate the discovery of next-generation antibody modalities SAN DIEGO, Calif. – November 1, 2021 – AlivaMab Discovery ...
CONTINUE READING

September 14, 2021

AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals

Agreement aims to accelerate the discovery of new therapeutics SAN DIEGO, Calif. – September 14, 2021 – AlivaMab Discovery Services (“ADS”), a ...
CONTINUE READING

December 14, 2020

AlivaMab Discovery Services Expands Drug Discovery Platform into Developability Assessment

Expansion gives AlivaMab Discovery Services the ability to streamline the transition of drug discovery programs into development SAN DIEGO, Calif ...
CONTINUE READING

June 3, 2020

AlivaMab Discovery Services (ADS) Announces Agreement with Tanabe Research Laboratories USA

ADS announces integrated antibody drug discovery collaboration SAN DIEGO, Calif. – June 3, 2020 – AlivaMab Discovery Services, LLC, a ...
CONTINUE READING

April 22, 2020

Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies

Offers unique resources for COVID-19 therapeutic discovery SAN DIEGO and EMERYVILLE, Calif. – April 22, 2020 – Ablexis, LLC, AlivaMab ...
CONTINUE READING

September 16, 2019

AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen

ADS to provide expertise and capabilities in antibody drug discovery SAN DIEGO, Calif. – September 16, 2019 – AlivaMab Discovery ...
CONTINUE READING

February 26, 2019

AlivaMab Discovery Services Identifies Highly Potent Antibodies in Two Months for Inaugural Client Project

Company Expands Team with Veterans of Antibody Discovery and Development SAN DIEGO, Calif. – February 26, 2019 – AlivaMab ...
CONTINUE READING

Resources

News

AlivaMab Biologics Announces Two Bispecific Antibody Presentations at SITC 2023

AlivaMab Discovery Services Changes Name to AlivaMab Biologics, Reflecting Its Continuing Expansion and Evolution

AlivaMab Discovery Services Appoints Ankita Srivastava, PhD, as Vice President, Antibody Engineering and Protein Sciences

Ablexis and AlivaMab Discovery Services Announce Expansion of Antibody Drug Discovery and Engineering Capabilities

AlivaMab Discovery Services Reappoints Dr. Larry Green as Chief Executive Officer

Ablexis and AlivaMab Discovery Services Announce Agreements with Almirall to Accelerate Antibody Drug Discovery and Development

AlivaMab Discovery Services Appoints Jane Seagal, PhD, as Vice President of Antibody Discovery

AlivaMab Discovery Services Expands Discovery Agreement with IGM Biosciences

AlivaMab Discovery Services Announces Multi-Target Agreement with Teva Pharmaceuticals

AlivaMab Discovery Services Expands Drug Discovery Platform into Developability Assessment

AlivaMab Discovery Services (ADS) Announces Agreement with Tanabe Research Laboratories USA

Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies

AlivaMab Discovery Services Announces Multi-Target Agreement with Janssen

AlivaMab Discovery Services Identifies Highly Potent Antibodies in Two Months for Inaugural Client Project

Case Studies

From Novel Assay Development to Quality Therapeutic Leads on a Rapid Timeline

Breaking Immune Tolerance to Generate Highly Potent Cross-Reactive Antibodies

Generating Diverse Antibodies Against Multi-Spanning Membrane Protein Targets

Upcoming Events

Antibody Engineering and Therapeutics, San Diego, California

PepTalk

Let’s Make Better Medicines Together